M.D. ANDERSON CANCER CENTER

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Cardiovascular Events Among Adults Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Standard of Care Chimeric Antigen Receptor T Cell Therapy

Recruiting

Conditions: Recurrent Diffuse Large B-Cell Lymphoma
Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma
Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
Refractory Diffuse Large B-Cell Lymphoma
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
Refractory High Grade B-Cell Lymphoma
Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
Recurrent High Grade B-Cell Lymphoma

Interventions: Other: Electronic Health Record Review

First Posted Date: 2021-05-04

Last Posted Date: 2023-11-14

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 150

Registration Number: NCT04870853

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Adoption of Audio Recording in the Outpatient Supportive Care Center

Not yet recruiting

Conditions: Advanced Malignant Solid Neoplasm
Locally Advanced Malignant Solid Neoplasm
Metastatic Malignant Solid Neoplasm
Hematopoietic and Lymphoid Cell Neoplasm
Recurrent Malignant Solid Neoplasm

Interventions: Other: Communication Intervention
Other: Questionnaire Administration

First Posted Date: 2021-05-04

Last Posted Date: 2025-01-24

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 200

Registration Number: NCT04871477

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Image-guided Proton Therapy for the Treatment of Locally Advanced Unresectable Head and Neck Cancer

Phase 1

Completed

Conditions: Stage II Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Malignant Posterior Tongue Neoplasm
Locally Advanced Laryngeal Squamous Cell Carcinoma
Locally Advanced Head and Neck Squamous Cell Carcinoma
Stage II Oropharyngeal (p16-Negative) Carcinoma AJCC v8
Locally Advanced Hypopharyngeal Squamous Cell Carcinoma
Stage II Laryngeal Cancer AJCC v8
Locally Advanced Nasopharyngeal Squamous Cell Carcinoma
Locally Advanced Oral Cavity Squamous Cell Carcinoma
Locally Advanced Oropharyngeal Squamous Cell Carcinoma

Interventions: Radiation: Proton Beam Radiation Therapy
Other: Quality-of-Life Assessment
Other: Questionnaire Administration

First Posted Date: 2021-05-04

Last Posted Date: 2024-10-29

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 3

Registration Number: NCT04870840

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Mindfulness-Based Intervention for Latino Cancer Patients and Their Caregivers

Not Applicable

Recruiting

Conditions: Advanced Malignant Solid Neoplasm

Interventions: Behavioral: Mindfulness Relaxation
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
Other: Group II (mindfulness waitlist)

First Posted Date: 2021-05-03

Last Posted Date: 2024-12-27

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04870788

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Customized 3D Printed Oral Stents During Head and Neck Radiotherapy

Phase 2

Recruiting

Conditions: Nasal Cavity Carcinoma
Tonsillar Carcinoma
Malignant Parotid Gland Neoplasm
Maxillary Sinus Carcinoma
Oral Cavity Carcinoma
Tongue Carcinoma
Head and Neck Carcinoma

Interventions: Other: Best Practice
Other: Medical Device Usage and Evaluation

First Posted Date: 2021-05-03

Last Posted Date: 2025-04-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 93

Registration Number: NCT04870762

Locations: 🇺🇸
Community MD Anderson Cancer Center East, Indianapolis, Indiana, United States
🇺🇸
Community MD Anderson Cancer Center South, Indianapolis, Indiana, United States
🇺🇸
Community MD Anderson Cancer Center North, Indianapolis, Indiana, United States

and more 4 locations

Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis

Not Applicable

Completed

Conditions: Malignant Solid Neoplasm

Interventions: Procedure: Advanced Magnetic Resonance Imaging
Procedure: Conventional Magnetic Resonance Imaging
Drug: Gadolinium-Chelate
Drug: Iopamidol

First Posted Date: 2021-05-03

Last Posted Date: 2024-11-06

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 15

Registration Number: NCT04870645

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

NBTXR3, Radiation Therapy, and Pembrolizumab for the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Cancer

Phase 2

Recruiting

Conditions: Recurrent Head and Neck Squamous Cell Carcinoma
Metastatic Head and Neck Squamous Cell Carcinoma

Interventions: Other: Hafnium Oxide-containing Nanoparticles NBTXR3
Radiation: Hypofractionated Radiation Therapy
Biological: Pembrolizumab
Radiation: Stereotactic Body Radiation Therapy

First Posted Date: 2021-04-28

Last Posted Date: 2024-04-15

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 60

Registration Number: NCT04862455

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Itacitinib for the Prevention of Graft Versus Host Disease

Phase 1

Active, not recruiting

Conditions: Hematologic and Lymphocytic Disorder

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Busulfan
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Itacitinib
Drug: Tacrolimus
Drug: Thiotepa

First Posted Date: 2021-04-26

Last Posted Date: 2025-05-22

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 31

Registration Number: NCT04859946

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia

Phase 1

Completed

Conditions: Secondary Acute Myeloid Leukemia

Interventions: Drug: Cladribine
Drug: Cytarabine
Drug: Uproleselan

First Posted Date: 2021-04-19

Last Posted Date: 2025-05-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 37

Registration Number: NCT04848974

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer

Phase 1

Active, not recruiting

Conditions: Stage IIIC Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8
Metastatic Lung Non-Small Cell Carcinoma
Recurrent Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8

Interventions: Biological: Bevacizumab
Drug: Carboplatin
Drug: Ensartinib
Drug: Pemetrexed

First Posted Date: 2021-04-08

Last Posted Date: 2025-03-03

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 12

Registration Number: NCT04837716

Locations: 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States

Home Terms & Conditions Privacy Policy